Quince Therapeutics (NASDAQ:QNCX) Stock Rating Raised to “Strong-Buy” at Rodman & Renshaw

Quince Therapeutics (NASDAQ:QNCX) was upgraded by equities researchers at Rodman & Renshaw to a “strong-buy” rating in a research note issued on Thursday, Zacks reports.

Several other research firms also recently commented on QNCX. Zacks Research upgraded shares of Quince Therapeutics to a “hold” rating in a report on Wednesday, June 24th. Leerink Partners began coverage on shares of Quince Therapeutics in a report on Wednesday, June 24th. They set an “outperform” rating and a $80.00 target price for the company. Oppenheimer assumed coverage on shares of Quince Therapeutics in a report on Wednesday, July 29th. They issued an “outperform” rating and a $82.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $70.00 price objective on shares of Quince Therapeutics in a report on Tuesday, August 18th. Finally, Lifesci Capital raised Quince Therapeutics to a “strong-buy” rating in a research report on Monday, June 29th. Three research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $206.71.

Quince Therapeutics Stock Down 0.5%

NASDAQ:QNCX opened at $30.00 on Thursday. Quince Therapeutics has a 12-month low of $15.10 and a 12-month high of $909.98. The firm has a market capitalization of $30.60 million, a price-to-earnings ratio of -0.19 and a beta of 1.31. The stock’s 50 day moving average price is $28.41 and its two-hundred day moving average price is $23.97.

Quince Therapeutics (NASDAQ:QNCX) last issued its earnings results on Friday, August 14th. The company reported ($12.31) EPS for the quarter, topping the consensus estimate of ($28.02) by $15.71.

Institutional Investors Weigh In On Quince Therapeutics

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in Quince Therapeutics in the second quarter valued at $31,000. Intellectus Partners LLC bought a new position in Quince Therapeutics during the 4th quarter worth $179,000. Finally, 683 Capital Management LLC acquired a new position in Quince Therapeutics during the 4th quarter worth about $798,000. Institutional investors and hedge funds own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The company’s research centers on its erythrocyte-derived extracellular vesicle (EEV) platform, which uses patients’ red blood cells to encapsulate and deliver therapeutic compounds.

Quince’s lead investigational product is eDSP, formerly known as EryDex, an autologous red-blood-cell-based formulation of dexamethasone sodium phosphate being developed for ataxia-telangiectasia (A-T).